Report Overview:
Human milk oligosaccharides (HMOs) are a family of structurally diverse unconjugated glycans that are found in and unique to human breast milk, despite not actually being digestible by human infants. HMOs function as a prebiotic helping to establish commensal bacteria. HMOs also function as anti-adhesives that help prevent the attachment of microbial pathogens to mucosal surfaces. Human milk oligosaccharides are manufactured through numerous processes which involve the use of several chemicals, enzymes or microbes. The technology used for manufacturing of human milk oligosaccharides is very complex and expensive, thus restricting their large-scale production. Major players have been increasing investing increasingly on R&D for lowcost production and the introduction of effective technologies for product synthesis.
This report provides a deep insight into the global Human Milk Oligosaccharides market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
Market Value:
The global Human Milk Oligosaccharides market size was estimated at USD 384.90 million in 2024 and is projected to reach USD 520.04 million by 2032, exhibiting a CAGR of 3.40% during the forecast period.
By Types:
• Fucosyllactose
• LNT & LNNT
• Sialyllactose
By Applications: Food
& Beverages
Food Supplements
Health Ingredients for Human and Animal
Infant Formulas
Key players include:
• Elicityl
• Glycom
• Glycosyn
• Inbiose
• Jennewein
• Medolac
• ZuChem
• Dextra
• Including or Excluding key companies relevant to your analysis.
